Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

Healthcare Biotechnology
"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

TELESTA THERAPEUTICS INC > lies or creative wording??
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by kristian7on Oct 26, 2016 8:51am
184 Views
Post# 25386488

RE:RE:RE:RE:lies or creative wording??

RE:RE:RE:RE:lies or creative wording??

ProMetic's Plasminogen Meets Primary And Secondary End Points In Pivotal Phase 2/3 Trial

Wednesday, October 26, 2016

 

ProMetic's plasminogen meets primary and secondary end points in pivotal Phase 2/3 trial

06:30 EDT Wednesday, October 26, 2016


  • *** 100% success rate on meeting clinical trial's primary end points required for Accelerated Approval Regulatory Pathway
  •  
  • *** 100% clinical response rate with healing of lesions within weeks of treatment
  •  
  • *** Successful pre-BLA meeting held with FDA
  •  
  • *** ProMetic to commence filing plasminogen BLA modules with the FDA as planned in coming weeks

Read more at https://www.stockhouse.com/companies/bullboard?symbol=t.pli&postid=25386255#7f50ym3dEquKAG67.99
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities